Portal de Periódicos da CAPES

Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours

2023; Elsevier BV; Volume: 80; Issue: 3 Linguagem: Inglês

10.1016/j.jhep.2023.10.040

1600-0641

Ciro Celsa, Giuseppe Cabibbo, Claudia Angela Maria Fulgenzi, Bernhard Scheiner, Antonio D’Alessio, Giulia Francesca Manfredi, Naoshi Nishida, Celina Ang, Thomas U. Marron, Anwaar Saeed, Brooke Wietharn, Matthias Pinter, Jaekyung Cheon, Yi‐Hsiang Huang, Pei‐Chang Lee, Samuel Phen, Anuhya Gampa, Anjana Pillai, Caterina Vivaldi, Francesca Salani, Gianluca Masi, Natascha Roehlen, Robert Thimme, Arndt Vogel, Martin Schönlein, Johann von Felden, Kornelius Schulze, Henning Wege, Peter R. Galle, Masatoshi Kudo, Lorenza Rimassa, Amit G. Singal, Paul El Tomb, Susanna V. Ulahannan, Alessandro Parisi, Hong Jae Chon, Wei‐Fan Hsu, Bernardo Stefanini, Elena Verzoni, Raffaele Giusti, Antonello Veccia, Annamaria Catino, Giuseppe Aprile, Pamela Francesca Guglielmini, Marilena Di Napoli, Paola Ermacora, Lorenzo Antonuzzo, Ernesto Rossi, Francesco Verderame, Fable Zustovich, Corrado Ficorella, Francesca Romana Di Pietro, Nicola Battelli, Giorgia Negrini, Francesco Grossi, Roberto Bordonaro, Stefania Pipitone, Maria Banzi, Serena Ricciardi, Letizia Laera, Antonio Russo, Ugo De Giorgi, Luigi Cavanna, Mariella Sorarù, Vincenzo Montesarchio, Paola Bordi, Leonardo Brunetti, Carmine Pinto, Melissa Bersanelli, Calogero Cammà, Alessio Cortellini, David J. Pinato,

Cancer therapeutics and mechanisms

Immune-related liver injury (irLI) is commonly observed in patients with cancer treated with immune checkpoint inhibitors (ICIs). We aimed to compare the incidence, clinical characteristics, and outcomes of irLI between patients receiving ICIs for hepatocellular carcinoma (HCC) vs. other solid tumours.